CAMP4 THERAPEUTICS CORPORATION logo

CAMP4 THERAPEUTICS CORPORATION(CAMP)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 7 days
PROFIT SINCE LAST BUY
-5.31% ▼
LAST CLOSE
$4.1
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CAMP

11/18/2026: CAMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Camp4 Therapeutics Corporation is a clinical-stage biotechnology company specializing in regulatory RNA-based therapeutics designed to upregulate gene expression for rare genetic diseases. The company's primary strength lies in its proprietary platform and pipeline candidates like CMP-001 and CMP-002 targeting severe liver and central nervous system disorders. Its core investment story centers on expanding platform capabilities and advancing clinical pipelines toward upcoming data readouts. However, the company faces substantial execution, financial, and clinical risks typical of pre-revenue biotechnology firms dependent on external capital. This stock is best suited for growth-oriented or speculative investors comfortable with high volatility and binary clinical milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers exposure to novel RNA platform science but carries high clinical development risk.
Momentum investorStrong fit while signal remains positiveCan experience sharp price movements around clinical trial readouts and regulatory updates.
Value investorWeak fitLacks earnings, profitability, and positive cash flow required for traditional value metrics.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical research.
Low-risk investorWeak fitHigh volatility and early-stage biotechnology risks make it unsuitable for conservative profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap clinical biotechnology shares frequently experience sharp price swings.
Valuation riskHighValuations are driven by pipeline potential rather than current revenue or earnings.
Competition risk (genetic medicine and RNA therapeutic competition)Medium / highThe company faces intense competition from well-funded peers developing genomic medicines.
Business qualityMediumThe proprietary regulatory RNA platform shows scientific promise but remains unproven commercially.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends entirely on navigating complex clinical trials and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 251.02M USD
Price to earnings Ratio -
1Y Target Price 10.22
Price to earnings Ratio -
1Y Target Price 10.22
Volume (30-day avg) 140.2K shares
Beta 0.28
52 Weeks Range 2.90 - 7.75
Updated Date 11/18/2026
52 Weeks Range 2.90 - 7.75
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.2

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -75.18%
Avg. Invested days 9
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CAMP receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CAMP has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+436.5%) is partially offset by negative earnings growth (-55.2%), weak cash generation (FCF margin -852.8%), weak profitability (net margin -2298.5%).

Financial Health Rating

★★★★★
CAMP's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 83.7%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CAMP's strongest growth driver at +436.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+35.2%, strong) is also strong, while earnings growth (-55.2%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 94.7% and approximately 60.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 9.04% supports management-shareholder alignment.

Top 5 Institutional Investors

Jupiter Topco LLC 10.05%
5AM Venture Management, LLC 9.35%
FMR Inc 7.82%
Vivo Capital, LLC 6.77%
Balyasny Asset Management LLC 4.10%

Unit Economics (Per $1K Revenue)

★★★★★
CAMP generates approximately $531 of gross profit, $-14,883 of operating income, and $-8,528 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CAMP has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Research and Development CollaborationsUpfront payments, research funding, and milestone fees from collaborative partnerships or research grants.Revenue is currently minimal and episodic, derived primarily from research collaborations rather than commercial product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 124.16M
Price to Sales(TTM) 47.18
Enterprise Value 124.16M
Price to Sales(TTM) 47.18
Enterprise Value to Revenue 23.34
Enterprise Value to EBITDA -
Shares Outstanding 62.75M
Shares Floating 37.81M
Shares Outstanding 62.75M
Shares Floating 37.81M
Percent Insiders 9.04
Percent Institutions 94.69

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.